Krka (KRK) Q1 2025 earnings summary

Executive summary

• Q1 2025 sales reached €522.1m, up 7–8% year-over-year, with net profit at €152.5m, a 51–54% increase year-over-year.

• 94% of sales were outside Slovenia; exports accounted for 96% of product sales.

• Share price rose 24% since year-end 2024, with market capitalization at €5.5–5.6 billion.

• Four new prescription pharmaceuticals launched; over 200 marketing authorizations finalized.

• Strong financial position with no significant leverage and robust cash generation.

Financial highlights

• EBITDA margin at 27.9%, EBIT margin at 23.5%, and gross profit margin at 58.3%.

• Net profit margin rose to 29.2% from 20.3% year-over-year; ROE at 26.2%, ROA at 20.5%.

• EPS increased to €19.87 (+55% year-over-year); book value per share at €73.98.

• Net financial result benefited from €56.8m FX gains, mainly RUB.

• Cash and cash equivalents reached €467.6m (+36% from year-end 2024).

Outlook and guidance

• 2025 sales guidance raised to over €2,000m, with net income guidance at €365m.

• CAPEX for 2025 planned at €150m, mainly for production expansion.

• Employee headcount expected to rise by 1% in 2025.